These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 33119877)

  • 1. γδ T Cells in Tumor Microenvironment.
    Imbert C; Olive D
    Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells.
    Boutin L; Scotet E
    Front Immunol; 2018; 9():828. PubMed ID: 29731756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human Vγ9Vδ2 T Cells.
    Peigné CM; Léger A; Gesnel MC; Konczak F; Olive D; Bonneville M; Breathnach R; Scotet E
    J Immunol; 2017 Jun; 198(11):4228-4234. PubMed ID: 28461569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy with γδ T cells: many paths ahead of us.
    Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
    Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γδ cells and tumor microenvironment: A helpful or a dangerous liason?
    Lo Presti E; Di Mitri R; Pizzolato G; Mocciaro F; Dieli F; Meraviglia S
    J Leukoc Biol; 2018 Mar; 103(3):485-492. PubMed ID: 29345336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy.
    Chabab G; Barjon C; Bonnefoy N; Lafont V
    Front Immunol; 2020; 11():2186. PubMed ID: 33042132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gammadelta T cell modulation in anticancer treatment.
    Caccamo N; Dieli F; Meraviglia S; Guggino G; Salerno A
    Curr Cancer Drug Targets; 2010 Feb; 10(1):27-36. PubMed ID: 20088797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
    Miyashita M; Shimizu T; Ashihara E; Ukimura O
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment.
    Kone AS; Ait Ssi S; Sahraoui S; Badou A
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Structural Change in Butyrophilin upon Phosphoantigen Binding Underlies Phosphoantigen-Mediated Vγ9Vδ2 T Cell Activation.
    Yang Y; Li L; Yuan L; Zhou X; Duan J; Xiao H; Cai N; Han S; Ma X; Liu W; Chen CC; Wang L; Li X; Chen J; Kang N; Chen J; Shen Z; Malwal SR; Liu W; Shi Y; Oldfield E; Guo RT; Zhang Y
    Immunity; 2019 Apr; 50(4):1043-1053.e5. PubMed ID: 30902636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. γδ T Cells in the Tumor Microenvironment-Interactions With Other Immune Cells.
    Chan KF; Duarte JDG; Ostrouska S; Behren A
    Front Immunol; 2022; 13():894315. PubMed ID: 35880177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune recognition of phosphoantigen-butyrophilin molecular complexes by γδ T cells.
    Uldrich AP; Rigau M; Godfrey DI
    Immunol Rev; 2020 Nov; 298(1):74-83. PubMed ID: 33017054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing γδ T cell biology.
    Vantourout P; Laing A; Woodward MJ; Zlatareva I; Apolonia L; Jones AW; Snijders AP; Malim MH; Hayday AC
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):1039-1044. PubMed ID: 29339503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells.
    Cano CE; Pasero C; De Gassart A; Kerneur C; Gabriac M; Fullana M; Granarolo E; Hoet R; Scotet E; Rafia C; Herrmann T; Imbert C; Gorvel L; Vey N; Briantais A; le Floch AC; Olive D
    Cell Rep; 2021 Jul; 36(2):109359. PubMed ID: 34260935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpaca (
    Fichtner AS; Karunakaran MM; Gu S; Boughter CT; Borowska MT; Starick L; Nöhren A; Göbel TW; Adams EJ; Herrmann T
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6697-6707. PubMed ID: 32139608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation.
    Starick L; Riano F; Karunakaran MM; Kunzmann V; Li J; Kreiss M; Amslinger S; Scotet E; Olive D; De Libero G; Herrmann T
    Eur J Immunol; 2017 Jun; 47(6):982-992. PubMed ID: 28386905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity.
    Blazquez JL; Benyamine A; Pasero C; Olive D
    Front Immunol; 2018; 9():1601. PubMed ID: 30050536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
    Bonneville M; Scotet E
    Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.